Anti-TNF and Crohn's Disease: When Should we Start?

E-ISSN： 1873-5592|11|2|143-147

ISSN： 1389-4501

Source： Current Drug Targets, Vol.11, Iss.2, 2010-02, pp. : 143-147

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-TNF and Crohn's Disease: When Should We Stop?

Current Drug Targets, Vol. 11, Iss. 2, 2010-02 ,pp. : 148-151

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-TNF agents in Crohn’s disease

By Assche G.V. Rutgeerts P.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 1, 2000-01 ,pp. : 103-111

Informa Healthcare

Access to resources Recommend Favorite

Phosphate binders in chronic kidney disease. When should we start, what should we prescribe?

By Malindretos Pavlos

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 16, 2012-11 ,pp. : 2255-2256

Informa Healthcare

Access to resources Recommend Favorite

The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn’’s disease

By Mascheretti Silvia Schreiber Stefan

Pharmacogenomics, Vol. 5, Iss. 5, 2004-09 ,pp. : 479-486

Future Medicine

Access to resources Recommend Favorite

Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?

Current Drug Targets, Vol. 14, Iss. 12, 2013-11 ,pp. : 1421-1432

Bentham Science Publishers

Access to resources Recommend Favorite